β5c (Cell Signaling Technology Inc)
Structured Review

β5c, supplied by Cell Signaling Technology Inc, used in various techniques. Bioz Stars score: 93/100, based on 55 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/anti+%CE%B25c/PSMB5+Rabbit+mAb/pmc12751025-282-29-38
Average 93 stars, based on 55 article reviews
Images
1) Product Images from "α‑Aminoboronic Acid Moieties in Boro Dipeptides Modulate Proteasome Subunit Selectivity and Provide Access to Compounds with Potent Anticancer and Anti-Inflammatory Activity"
Article Title: α‑Aminoboronic Acid Moieties in Boro Dipeptides Modulate Proteasome Subunit Selectivity and Provide Access to Compounds with Potent Anticancer and Anti-Inflammatory Activity
Journal: Journal of Medicinal Chemistry
doi: 10.1021/acs.jmedchem.5c02548
Figure Legend Snippet: Effect of compounds 5b , 5c , and 5j – l , as well as subunit selective control compounds on the secretion of cytokines in LPS-stimulated PBMCs. All compounds were tested at 250 nM. The cells were pretreated for 1 h with inhibitors, followed by the addition of LPS (1 μg/mL). As the negative control (designated by ‘DMSO’ in figure legends), cells were treated only with DMSO, followed by the addition of LPS (1 μg/mL). The concentrations of cytokines were determined in the supernatants after additional 24 h treatment. The results are represented as means ± SD of four independent experiments ( N = 4). Statistical significance between untreated controls versus treated was calculated using one-way ANOVA post hoc Dunnett’s test. A p -value of less than 0.05 was considered significant (**** p < 0.0001; *** p < 0.001; ** p < 0.01; * p < 0.05).
Techniques Used: Control, Negative Control
Related Articles
Polyacrylamide Gel Electrophoresis:Article Title: Design and Evaluation of Highly Selective Human Immunoproteasome Inhibitors Reveal a Compensatory Process That Preserves Immune Cell Viability. Article Snippet: The pan-proteasome inhibitor bortezomib demonstrated clinical efficacy in off-label trials of Systemic Lupus Erythematosus.. One potential mechanism of this clinical benefit is from the depletion of pathogenic immune cells (plasmablasts and plasmacytoid dendritic cells).. However, bortezomib is cytotoxic against non-immune cells which limits its use for autoimmune diseases. Membrane:Article Title: Design and Evaluation of Highly Selective Human Immunoproteasome Inhibitors Reveal a Compensatory Process That Preserves Immune Cell Viability. Article Snippet: The pan-proteasome inhibitor bortezomib demonstrated clinical efficacy in off-label trials of Systemic Lupus Erythematosus.. One potential mechanism of this clinical benefit is from the depletion of pathogenic immune cells (plasmablasts and plasmacytoid dendritic cells).. However, bortezomib is cytotoxic against non-immune cells which limits its use for autoimmune diseases. Blocking Assay:Article Title: Design and Evaluation of Highly Selective Human Immunoproteasome Inhibitors Reveal a Compensatory Process That Preserves Immune Cell Viability. Article Snippet: The pan-proteasome inhibitor bortezomib demonstrated clinical efficacy in off-label trials of Systemic Lupus Erythematosus.. One potential mechanism of this clinical benefit is from the depletion of pathogenic immune cells (plasmablasts and plasmacytoid dendritic cells).. However, bortezomib is cytotoxic against non-immune cells which limits its use for autoimmune diseases. |